Bristol Myers Squibb Completes Acquisition of RayzeBio
Feb 27, 2024 07:21
CST Updated
07:21
Bristol-Myers Squibb
Biopharmaceutical and Nutritional Product R&D and Sales
RayzeBio
Targeted Drug Developer
Bristol Myers Squibb announced on February 26 that it has completed the acquisition of biopharmaceutical company RayzeBio, making RayzeBio a wholly-owned subsidiary of Bristol Myers Squibb. (Jiemian)Original Link